Climb Bio Stock Current Valuation
| CLYM Stock | 2.10 0.17 7.49% |
Valuation analysis of Climb Bio helps investors to measure Climb Bio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 30th of December 2024, Cash is likely to drop to about 56.1 M.
Overvalued
Today
Please note that Climb Bio's price fluctuation is dangerous at this time. Calculation of the real value of Climb Bio is based on 3 months time horizon. Increasing Climb Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Climb stock is determined by what a typical buyer is willing to pay for full or partial control of Climb Bio. Since Climb Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Climb Stock. However, Climb Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.1 | Real 2.02 | Hype 1.46 |
The intrinsic value of Climb Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Climb Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Climb Bio helps investors to forecast how Climb stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Climb Bio more accurately as focusing exclusively on Climb Bio's fundamentals will not take into account other important factors: Climb Bio Company Current Valuation Analysis
Climb Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Climb Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Climb Bio is extremely important. It helps to project a fair market value of Climb Stock properly, considering its historical fundamentals such as Current Valuation. Since Climb Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Climb Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Climb Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Climb Bio has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Climb Bio is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 10.27 Billion. Climb Bio adds roughly 0.0 in current valuation claiming only tiny portion of stocks in Biotechnology industry.Climb Fundamentals
| Net Income | (35.12 M) | ||||
| Total Debt | 2.87 M | ||||
| Total Asset | 110.47 M | ||||
| Retained Earnings | (155.98 M) | ||||
| Working Capital | 107.42 M | ||||
| Net Asset | 110.47 M |
About Climb Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Climb Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Climb Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Climb Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Climb Bio Piotroski F Score and Climb Bio Altman Z Score analysis. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.